We determined the electrocardiographic, vascular and clinical effects of a medical food bar enriched with L-arginine and a combination of other nutrients known to enhance endothelium-derived nitric oxide (NO) in patients with stable angina. BACKGROUND Enhancement of vascular NO by supplementation with L-arginine and other nutrients has been shown to have clinical benefits in patients with angina secondary to atherosclerotic coronary artery disease (CAD). However, the amounts and combinations of these nutrients required to achieve a clinical effect make traditional delivery by capsules and pills less suitable than alternative delivery methods such as a specially formulated nutrition bar.
Atherosclerotic coronary artery disease (CAD) is responsible for angina and is the leading cause of mortality in the developed world. Many risk factors for CAD are associated with a reduced elaboration of nitric oxide (NO) by the endothelium (1) (2) (3) . A new therapeutic strategy for individuals with CAD is to restore NO activity, thereby facilitating vasodilation and increasing resistance to thrombosis and atherosclerosis. For example, the restoration of vascular NO activity by HMG CoA reductase inhibitors is associated
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with improvements in vasodilation and a reduction in cardiovascular mortality beyond that which would be expected from their effects on lipid levels and vascular structure (4, 5) . A number of naturally occurring products may also enhance vascular NO activity. Among these is L-arginine, the precursor to NO, as well as folic acid, vitamins B6 and B12, vitamin C, vitamin E, phytoestrogens and niacin (6 -15) .
Accordingly, a medical food was developed that contains L-arginine and these additional nutrients. In previous studies this medical food was demonstrated to improve flowmediated vasodilation in middle-aged individuals with hypercholesterolemia and to increase walking distance and enhance quality of life in patients with claudication secondary to peripheral arterial disease (16, 17) . This study was designed to study the vascular, electrocardiographic and clinical effects of this medical food in patients with stable angina.
METHODS
Study design. The study was a randomized, double-blind, placebo-controlled crossover trial of dietary supplementation for two-week treatment periods with two active bars/ day (active period) and two placebo bars/day (placebo period). The short course of therapy was chosen so that the acute vascular effects of the bar could be assessed in isolation from any beneficial effects that it may have on vascular structure, inflammation and thrombosis.
The first treatment period was preceded by the collection of baseline data (baseline period), and the two treatment periods were separated by a month-long washout (washout period). The primary objective of the study was to examine the effect of the treatments on the time to onset of ST-segment depression compared with before treatments. Secondary outcomes include other treadmill exercise parameters, ambulatory electrocardiogram (ECG) (Holter) measures, quality-of-life measures, Medical Outcomes Study Health Survey (SF-36) and Seattle Angina Questionnaire scores and measures of flow-mediated endothelial function. All subjects signed an informed consent before undergoing screening procedures. At the screening visit, a medical history was collected, and a physical exam and treadmill testing were performed. Qualifying subjects returned for baseline treadmill testing, a brachial artery ultrasound study, quality-of-life measures and 48-h Holter monitoring during routine daily activities. Venous blood samples were taken for determination of serum lipid, chemistry and hematologic values. Subjects were randomized to begin one or the other treatment periods after removal of the Holter monitor. Subjects were instructed to take the study bars with or between meals separated by at least 4 h. Subjects were also instructed in the use of the study diary. At the end of both two-week treatment periods and the four-week washout period, subjects returned for repeat studies after an overnight fast and 1 to 2 h after consuming the last study bar. Subjects were also instructed to continue their current medications but withhold any doses of beta-adrenergic blocking agents and nitrate-containing drugs scheduled within 4 h of treadmill testing until after the procedure. The procedures followed in this study were in accordance with the ethical standards of the approving independent review board and with the Helsinki Declaration of 1975, as revised in 1983. Subjects. Eligible subjects were adults with chronic, stable angina (Canadian Cardiovascular Society class II and III) with ST-segment depression of 1 mm or more before achieving 14.5 metabolic equivalents of the task (METS) during treadmill exercise testing. The presence of CAD was verified by documented evidence of a myocardial infarction, an abnormal stress test or coronary angiogram demonstrating Ն50% luminal obstruction of Ն1 epicardial coronary artery or major branch. Subjects were excluded if they had unstable angina (rest angina or a change in clinical condition within the previous two months), a myocardial infarction, major surgery or angioplasty within the previous three months, symptomatic heart failure, impaired renal or hepatic function or any other systemic illness. Subjects were also excluded for presence of congenital heart disease, valvular heart disease, atrial fibrillation, uncontrolled hypertension, type I diabetes, any disease process other than CAD that would cause early termination of treadmill testing and hypersensitivity to any components in the bar. Subjects were required to discontinue L-arginine and L-lysine-containing products 28 days before acquiring baseline data. Subjects were otherwise asked to continue their regular medications, diet and lifestyle habits and were free to follow any other medical care regimens. Study product. The active bar is an L-arginine-enriched nutrient bar (HeartBar, Cooke Pharma, Silver Springs, Maryland). Each 50-g active bar contains 3.3 g of L-arginine as well as antioxidant vitamins and minerals, folic acid and B vitamins in a soy protein and oat fiber base. Each placebo bar is similar to the active bar with respect to weight, appearance and flavor as well as caloric, carbohydrate, protein, fiber and fat content but is not supplemented with L-arginine and is devoid of added vitamins and minerals. In addition, the protein source of the placebo bar is mixed milk protein and whey (which are L-argininepoor) rather than soy (L-arginine-rich). The components of the active and placebo bars are listed in Table 1 . All bars were individually wrapped in plain white wrappers. Both wrappers and cases containing the bars were coded in order to keep subjects and study personnel blinded. Previous studies demonstrated that subjects are unable to distinguish between active and placebo bars by appearance, taste, texture or outer markings. (20 -22) . The Seattle Angina Questionnaire has been validated and found to relate to Canadian Cardiovascular Society classification and to be sensitive to changes in disease over time (23) . Using the study diary, subjects were asked to record any chest pain episodes and the use of nitroglycerin. Safety and adverse events. Safety was monitored by survey for adverse events and by analyses of serum lipid, chemistry and hematology, which were performed by Unilab (San Jose, California 
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RESULTS
Demographics.
Of 86 individuals screened, 36 met the inclusion/exclusion criteria and were randomized. The reasons for screening failure included failure to attain 1-mm ST-segment depression before treadmill termination (n ϭ 23), abnormal rhythm interfering with interpretation (n ϭ 9), insufficient independent documentation of CAD (n ϭ 7) and miscellaneous (n ϭ 11). The characteristics of the subjects in each group are given in Table 2 . There were no dropouts during the 10-week study. All patients remained above 75% compliance during both periods (97 Ϯ 1% and 99 Ϯ 2% for the active and placebo periods, respectively) except for one patient who maintained 57% compliance during the placebo period. There were no statistical differences in any measures of outcomes between initial baseline and washout periods, demonstrating that the month-long washout period was sufficient to return to baseline values. Exercise treadmill testing. All subjects developed 1-mm ST-segment depression at screening. Thirty-one subjects developed 1-mm ST-segment depression during the active period while 28 developed 1-mm ST-segment depression during the placebo period. There was no treatment effect on the time to onset of 1-mm ST-segment depression by either mixed model or rank-sum testing (Table 3) . While there was no effect on the time to onset of ST-segment depression, total exercise time increased by 16% on average in the active period compared with a 4% decrease in treadmill time during the placebo period (p ϭ 0.05). A tendency toward increased total work performed (METS-min) was observed in the active period (ϩ27% on average), compared with a decrease (Ϫ6% on average) during the placebo period (p ϭ 0.06). Despite the increase in exercise time during the active period, there was no effect on the peak magnitude of ST-segment depression summed across all leads or on peak rate-pressure product during the active period.
Thirty-one subjects experienced angina during treadmill testing on at least one of the four phases. The percentage of patients who experienced angina during treadmill testing was similar during the active and placebo treatments (75% vs. 64%, p ϭ NS) ( Table 3 ). There was no treatment effect on the time to onset of angina. Table 4 . The improvement in the summary SF-36 can be attributed to the physical component with an improvement from baseline to the active period in the aggregate score from 41 Ϯ 9 to 44 Ϯ 9 (p ϭ 0.03). The difference between the active and placebo periods (41 Ϯ 11) was marginal (p ϭ 0.08) due to increased variability after the placebo period. No significant changes were seen for the aggregate mental score between any periods. Among the individual components, vitality and role-physical scores improved most significantly from baseline to the active period; however, only vitality and bodily pain scores during the active period were significantly better than those during the placebo period. The SF-36 aggregate physical component scores were converted to Z-scores (numbers of SD from a reference mean) to compare with the age-and gender-matched healthy population ( Table 4 ). The mean aggregate physical score was 0.87 SD below the healthy population at baseline. This score improved to 0.60 SD below the mean of the healthy population during the active period while there was no improvement during the placebo period. Summary Seattle Angina Questionnaire scores corroborated SF-36 results by showing improvement from baseline and in comparison with placebo scores (p ϭ 0.0004 and 0.04, respectively). Four of five components of the Seattle Angina Questionnaire significantly improved after the active period, although only treatment satisfaction was significantly better than that after the placebo period (Table 4) .
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Diary analysis demonstrated no change in chest pain frequency during any portion of the study (Table 4 ). There was, however, a decrease in nitroglycerin use during both treatment periods (p ϭ 0.003 and 0.002 for active and placebo periods, respectively). Evaluation of safety. There were no differences between the placebo and active periods in parameters of safety. There were no significant changes in values with respect to serum chemistry, hematologic or lipid levels except for a significant Baseline demographic and medical data of subjects. Alcoholic drinks of differing types were converted to one standard. ACE ϭ angiotensin-converting enzyme; BP ϭ blood pressure; CABG ϭ coronary artery bypass graft; CCS ϭ Canadian Cardiovascular Society. Treadmill data of subjects before and after two weeks of active and placebo treatment. *p Ͻ 0.05; **p Ͻ 0.01 vs. before intervention. †Values reported are for subpopulation that attained 1-mm ST segment depression or angina on all four occasions; p value: active vs. placebo by mixed model repeated measures analysis for all data except frequency data which was analyzed by chi-square.
MET ϭ metabolic equivalent of the task; TNG ϭ trinitroglycerin.
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or leg pain (two active), headache (one active, one placebo), outbreak of cold sores (one active), bloating (one active), increase in blood glucose (one active), hematochezia (one placebo), colitis (one placebo), increased fatigue (one placebo) and rash (one placebo).
DISCUSSION
This study indicates that this L-arginine-enriched medical food may be a useful nutritional adjunct to traditional medical therapy in patients with CAD. Specifically, our findings demonstrate that therapy with two active bars/day for two weeks significantly improved brachial artery NOmediated vascular function and improved treadmill exercise capacity by 20% compared with placebo. Due to the design of the ACIP protocol, this increase in exercise time results in a 33% increase in work performance. Despite the improvement in treadmill exercise capacity with therapy, there was no increase in electrocardiographic manifestations of ischemia or cardiac work as measured by rate-pressure product. These objective findings were associated with significant improvements in several parameters measuring quality of life. Study rationale. The rationale for this current investigation is provided by a series of studies over the past decade documenting that the administration of L-arginine can improve endothelium-dependent vasodilation, coronary blood flow and symptoms in patients with CAD. During coronary artery catheterization, a single intravenous infusion of L-arginine and long-term administration of oral L-arginine (9 g/day for six months) improve coronary blood flow response to acetylcholine in these patients (25) (26) (27) (28) (29) (30) (31) .
Similarly, an endothelial vasodilator dysfunction of the brachial artery exists in young men with documented CAD, which is reversed by L-arginine administration (32) . These beneficial effects of L-arginine on vasodilator function have clinical consequences. Concomitant with the reversal of endothelial vasodilator dysfunction in patients with CAD, L-arginine supplementation modestly lowers mean arterial pressure, reduces total peripheral resistance, increases cardiac output, increases exercise capacity and improves angina symptom scores (31, 33, 34) . L-arginine supplementation may also have beneficial effects on plaque formation; it appears to slow the progression and may even cause regression of atherosclerotic plaque in animals (35) .
Comparison with previous studies. In the current study, the 20% increase in treadmill exercise time in this population was similar to that which we reported for this therapy in patients with peripheral arterial disease (17) . In that study, patients with claudication were able to increase their total walking time by 23% after two weeks of therapy. They also demonstrated an improvement in pain-free walking distance (by 66%). These findings are also comparable with three other studies examining the effects of supplemental L-arginine on exercise capacity in patients with stable angina. In one, three days of oral supplementation with 6 g of L-arginine resulted in a 30% increase in work performance (34). These investigators followed their study with a second crossover study of three days duration (6) . In that study, there was a 7% increase in exercise duration and no change in the sum of ST-segment depression at peak exercise. Contrary to our findings, however, there was a 9% increase in the time to onset of 1-mm ST-segment depression. They also found no change in the amount of QT dispersion, an exercise-induced occurrence that is associated with greater risk of sudden cardiac death. In a third study, a one-time infusion of L-arginine resulted in no improvement in measures of exercise capacity but did decrease the time to recovery from myocardial ischemia (8) .
The increase in exercise time observed here compares favorably with recent studies of anti-anginal drug therapies. In a study comparing propranolol, diltiazem and nifedipine in patients with stable angina, only diltiazem improved exercise duration (by 8%) (36) . Another group reported a 12% increase over placebo in exercise duration for diltiazem after 12 weeks in a study comparing calcium channel blockers (37) . The Monotherapy Assessment of Ranolazine in Stable Angina (MARISA) investigators recently reported a 10% increase over placebo in symptom-limited exercise duration after one week during peak ranolazine levels (38) . In that study, subjects were withdrawn from other antianginal medications in order to increase the likelihood of observing an effect of therapy. By contrast, in the current study, patients continued on their existing anti-anginal medications throughout the investigation.
In contrast with the effects observed for exercise capacity, we did not observe any effects on angina onset time or ECG manifestations of ischemia during treadmill testing nor on cumulative ischemic time during routine ambulatory activities. The lack of beneficial effect on angina and ischemia onset times during treadmill testing may be partly explained by the fact that our study patients were receiving multiple anti-anginal therapies such as beta-blockers, organic nitrates and calcium channel blockers. Most studies designed to determine the effects of new anti-anginal therapies on ST-segment depression require the withdrawal of standard anti-anginal medications (particularly beta-blockers) before enrollment in order to assess efficacy of the study drug. However, because the medical food is a nutritional adjunct to standard medications, these medications were not withdrawn. Evidence for mechanism of action. The lack of effect on ECG manifestations of ischemia during maximal exercise should be placed in the context of the amount of work performed. Despite the same degree of ischemia at maximal exercise with active treatment as with placebo, subjects were able to exercise 20% more during the active period. The increased exercise time without an increase in degree of ischemia likely reflects a decrease in myocardial oxygen demand (i.e., decreased heart rate and blood pressure) during submaximal exercise, an anti-ischemia mechanism Quality-of-life data of subjects before and after two weeks of active and placebo treatment. SF-36 data are presented both as absolute scores and as Z-scores (SD from mean of healthy age-matched controls), which are given in italics next to the absolute scores. p value: active vs. placebo, *p Ͻ 0.05; †p Ͻ 0.01; ‡p Ͻ 0.005 vs. before intervention.
